Multiple Myeloma (MM) is a complex disease considered incurable in the
majority of patients; however, several new treatments have been developed over the
last decade, including third generation immunomodulatory drugs (pomalidomide),
second generation proteasome inhibitors (carfilzomib and ixazomib), a histone
deacetylase inhibitor (panobinostat) and monoclonal antibodies (elotuzumab and
daratumumab). In addition, some new agents with unique mechanisms of action are in
the process of development. Of these, isatuximab, oprozomib, filanesib (ARRY-520),
dinaciclib, venetoclax, selinexor, melflufen and LGH-447 are the most promising,
demonstrating preclinical single-agent activity against MM. In this chapter, we present
the current status of newer and investigational anti-myeloma agents, and outline future
directions for clinical use. We also summarize recent developments in the treatment of
MM patients, obtained through a thorough literature review of all WO, EP and US
patents filed in 2010-2018, using PubMed and http://ep.espacenet.com/ as sources. The
development of novel drugs will hopefully lead to therapies with more potent effects.
Keywords: Afuresertib, bortezomib, citarinostat, daratumumab, elotuzumab,
filanesib, ixazomib, isatuximab, lenalidomide, melflufen, nivolumab, oprozomib,
panobinostat, pembrolizumab, pomalidomide, ricolinostat, selinexor, trametinib,
venetoclax, vorinostat.
